((自动化翻译由路透提供，请见免责声明 )) (第2段增加股份，第3和第4段增加疾病详情，第5-7段增加背景资料)
路透9月19日 - 美国食品和药物管理局拒绝批准万达制药公司 治疗胃麻痹症状的药物。
该公司股价在盘前交易中下跌约14%，至4.26美元。
万达正在寻求卫生监管机构批准该公司的药物tradipitant用于治疗胃瘫，胃瘫是一种以胃排空延迟为特征的疾病。
胃瘫是一种以胃排空延迟为特征的疾病，患者会出现严重恶心、呕吐和难以完成正常进餐等症状。
万达公司从礼来 公司获得了替替匹坦的授权，目前也在研究它对晕车症的治疗作用。
卫生监管机构对替替匹坦实施了部分临床搁置，禁止进行超过12周的试验。
该公司计划在今年晚些时候提交一份单独的药物申请，以防止晕车呕吐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.